Compare Lionsgate Studios Corp Common Shares (LION) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs TransMedics Group Inc — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B), while TransMedics Group Inc trades at $75.52 (market cap $2.74B). The key difference: Lionsgate Studios Corp Common Shares is the larger of the two by market cap, and Lionsgate Studios Corp Common Shares is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and TransMedics Group Inc for 24 Days on average.
| LION | TMDX | |
|---|---|---|
Market Cap | $3.31B | $2.74B |
Volume | 2,146,134 | 1,025,926 |
Sector | Technology | Health |
52-Week High | $16.40 | $150.42 |
52-Week Low | $5.91 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $6.82B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
TMDX trades at $79.14, up 1.23% on the day, but faces a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Recent news highlights insider buying and a new CFO appointment, alongside multiple legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but near-term risks include earnings volatility, legal scrutiny, and a declining net cash flow trend. Investors should weigh solid fundamentals against execution and sentiment risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
